FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. The company is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Follow-Up Questions
Qui est le CEO de FibroGen Inc ?
Mr. Thane Wettig est le Chief Executive Officer de FibroGen Inc, il a rejoint l'entreprise depuis 2020.
Quelle est la performance du prix de l'action FGEN ?
Le prix actuel de FGEN est de $10.99, il a increased de 1.5% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de FibroGen Inc ?
FibroGen Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de FibroGen Inc ?
La capitalisation boursière actuelle de FibroGen Inc est de $44.4M
Est-ce que FibroGen Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour FibroGen Inc, y compris 2 achat fort, 4 achat, 2 maintien, 0 vente et 2 vente forte
